Conference Day Two
Thursday 27th February 2025
8:00 am Check in & Morning Coffee
8:50 am Chairperson’s Opening Remarks
Understanding Radiobiological Mechanisms of Killing & Immune Stimulation to Match Optimal Radiopharmaceutical Targets
9:00 am Understanding the Effects of Radiopharmaceuticals on Immune-Mediated Responses & Isotope Comparison on Anti-Tumor Immunity
Synopsis
- Comparing the immunologic effects of clinically-relevant radiopharmaceutical isotopes on anti-tumor immunity
- Exploring poorly immunogenic tumors with intrinsic resistance to ICIs, combination with high LET, short-range alpha-emitters may prime adaptive CD8+ T cell recognition
- Outlining acquired resistance to ICIs, low doses of low LET, longer range beta-emitting RPT may provide tumor inflammation and tumor cell susceptibility needed to renew clonal expansion of existing tumor-specific CD8+ T cells and generate immunologic memory
9:30 am Roundtables: Interrogating Radiopharmaceutical Mechanisms of Resistance to Build Strategies for Overcoming Them
Synopsis
- Identifying molecular drivers of resistance such as alterations in DNA repair pathways, tumor microenvironment changes, and efflux transporters
- Understanding how adaptive responses, such as changes in target expression or immune evasion, can lead to reduced effectiveness of radiopharmaceuticals
- Explore innovative strategies to overcome resistance
10:00 am Exploring CAR-T & Radiopharmaceutical Combinations in Solid Tumors for Enhanced Efficacy
Synopsis
- Appreciating that CAR T cells have shown limited effectiveness against solid tumors for various reasons
- Outlining the increasing evidence of the immunostimulatory effects of radiopharmaceutical therapy,
- Addressing some of the challenges faced by CAR T cell therapy especially in the metastatic setting
10:30 am Speed Networking & Morning Coffee Break
Rational Drug Design for Radiopharmaceuticals – Targeting Strategies
11:30 am Small Molecule Design, Strategy & Development for CAIX Targeting
Synopsis
- Exploring ligand engineering and design
- Uncovering strategy behind small molecule development
- Outlining selection of CAIX as a novel radiopharmaceutical target
12:00 pm Designing the Next Generation of Molecularly Targeted Radiotherapies (MTRs)
Synopsis
- Addressing limitations with safety and efficacy in solid tumors
- Tailoring next generation of MTRs for their PK/PD characteristics and tumour uptake
- Considering treating a broader range of tumors for improved patient benefit through novel targets
12:30 pm Lunch Break & Networking
Rational Drug Design for Radiopharmaceuticals – Chelator & Linker Developments
1:30 pm Linker Design Trends & Implications for Enhanced Radiopharmaceutical Agents’ PD/PK
Synopsis
- Covering the latest trends and innovations in linker design
- Appreciating implications for radiopharmaceutical properties
- Exploring strategies include plasma protein binding, covalent binding, charge and hydrophobicity, and enzymatic cleavage.
2:00 pm Advancing Chelator Technologies for Enhanced Radiopharmaceutical Development
Synopsis
- Promoting altered drug properties
- Outlining chelators of choice
- Improving the pharmacokinetics and biodistribution of radiopharmaceuticals
2:30 pm Roundtables: Overcoming Kidney Toxicities for Small Molecular Size: Modifications for Radiopharmaceuticals
Synopsis
- Exploring modifications to reduce kidney tox
- Minimizing off-target effects
- Utilizing reno protective agents
3:00 pm Afternoon Coffee Break & Networking
Exploring Radiation Absorption, Early Preclinical Dosimetry & Novel Assay Development
3:30 pm Roundtables: Future Thinking Predictive Modelling & Assays for Radiopharmaceuticals to Assess Translational Success
Synopsis
- Exploring the application of machine learning algorithms to analyze complex datasets
- Identify Patterns in Pharmacokinetics, biodistribution, and toxicity profiles, to develop robust predictive models that can forecast the translational success